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- 57] months, however this difference was not statistically signiﬁcant 
(p=0.56). In multi-variate analysis, T and N status (p<0.001), large cell 
undifferentiated and sarcomatoid histology (p=0.045 and 0.050) and 
female gender (p=0.029) were signiﬁcantly associated with survival 
but there was no evidence of interactions between the presence of AAH 
and any of these factors. 
Conclusion: In this case-control study the presence of AAH in lungs 
resected for primary carcinoma does not inﬂuence patient survival. 
More data are required on patients with large numbers of AAH to better 
understand the signiﬁcance in this group and determine clinical follow-
up strategy in AAH patients. 
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Background: 5-y surv in surgically resected St I NSCLC is 60-70% 
whereas in cases with affected lymph nodes (LN) it is < 50%. The main 
risk factor for recurrence is nodal disease. Current histopathologic 
analysis can miss occult micrometastases in nodal tissues at initial diag-
nosis. Detection of micromets with a more sensitive technique would 
be useful to deﬁne a high-risk population selecting patients (p) for po-
stop treatment. We assessed the role of several genes mRNA expression 
in pathological negative LN from resected St I NSCLC p as markers of 
occult micromets and correlated the results with relapse, and survival.
Methods: Paired tumor and histological negative LN (n=344) obtained 
by systematic mediastinal lymphadenectomy from 38 surgically 
resected St I NSCLC p were analyzed for the presence of 12 genes 
mRNA expression using RT-Q-PCR in an ABIPRISM 7500. RNA was 
extracted using ABIPRISM 6100. Speciﬁcally designed primers and 
probes were purchased from Applied Biosystems as Assay-on-demand; 
GADPH was used as an endogenous control. Samples were also ana-
lyzed by ICH for LN staging.
Results: 38 NSCLC p; 12 adenoca, 16 squamous cell, 10 undifferenti-
ated . From the 12 tested genes CEA and PLUNC were found with high 
expression in lung tissue and low or null expression in normal LN. We 
consider molecular + LN those in which expression of CEA or PLUNC 
was detected. In the 344 pathological negative LN, 13% (44/344) were 
positive for CEA, 16% (54/344) for PLUNC. The expression patterns 
were similar for both markers. At a median follow-up of 24 mo (9-46) 
11 p had died from NSCLC and 1 had died without recurrence. None 
of the living p had tumor recurrence. For the prognostic assessment, 
molecular + LN were classiﬁed as N1 and N2. Median DFS was 15 ± 
11.74 mo in p with N2 molecular + nodes and has not yet reached in 
cases of molecular (-) LN (p=0.028). Median survival of p with N2 
molecular positive nodes was 17.3 ± 5.7 mo and has not yet reached 
(p= 0.0083) for molecular (-) LN.
Conclusions: CEA and PLUNC mRNA expression could be used as 
molecular markers of occult micrometastases in mediastinal LN show-
ing a prognostic effect . CEA and PLUNC expression provides a tool 
for selecting high-risk p considered for adjuvant therapies
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Background: Akt (protein kinase B) is a key intracellular serine-threo-
nine kinase for transmission of cell survival (anti-apoptotic) signals. 
Activation of growth factor receptors results in phosphorylation and 
activation of Akt at S473 and T308. Multiple downstream survival sig-
nals are subsequently activated, which include among others fork-head 
transcription factor (FKHR), mTOR, Bad, and NFkB. PTEN inacti-
vates pAkt. Growth factor signaling is an important component in the 
progression of NSCLC, and clinical data suggest that it may be crucial 
for maintenance of the malignant phenotype in a subset of patients, 
particularly in adenocarcinomas, women, and those with a minimal 
smoking history. In addition, small and early-stage tumor may be more 
dependent on growth factor signaling than advanced and large tumors.
Methods: We used a novel, immunoﬂuorescence-based in situ protein 
detection method (AQUA) which allows for accurate, quantitative, and 
automated measurement of proteins in FFPE specimens in subcellular 
compartments. A tissue microarray that included 187 specimens from 
patients with completely resected stage I NSCLC that were not treated 
with (neo)adjuvant chemotherapy or radiation was constructed. After 
optimization of staining techniques, these specimens were evaluated for 
pAktS473, pAktT308, pFKHR, and PTEN expression, and results were 
analyzed for associations with clinicopathological parameters. Because 
of multiple comparison analysis, only associations with p-values =/< 
0.01 were considered interesting.
Results: There was a signiﬁcant positive correlation between 
pAkt(S473) and pFKHR expression (p<0.0001), and between 
pAkt(S473) and pAkt substrate expression (p<0.01). There was no 
association between pAkt(S473) and pAkt(T308) expression. PTEN 
and pAkt(T308) expression were inversely correlated (p<0.01), and 
PTEN and pAkt(S473) expression were positively correlated (p<0.01). 
Neither pAkt(S473) nor pAkt(T308) expression was signiﬁcantly as-
sociated with tumor histology (Kuskal Wallis test), gender (t-test), or 
smoking status. There was a signiﬁcant inverse correlation between 
tumor size and pAkt(T308) expression (p=0.001), which was not 
observed for pAkt(S473). Survival was better for patients with high cy-
toplasmic pAkt(S473) expression compared to low expression (p=0.02; 
HR=0.53; dichotomized by sample median), and for those with high 
nuclear pAkt(T308) (p=0.03; HR=0.56).
Conclusions: There is evidence for activity and clinical signiﬁcance of 
the Akt pathway in patients with early-stage NSCLC by AQUA analy-
sis of FFPE tumor specimens.
